Takeda Pharmaceutical Company Limited (TKPHF)
| Previous Close | 28.97 |
| Open | 28.97 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 28.97 - 28.97 |
| 52 Week Range | 26.03 - 34.68 |
| Volume | |
| Avg. Volume | 88,682 |
| Market Cap | 45.896B |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | 11.30 |
| EPS (TTM) | 2.60 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.38 (4.88%) |
| Ex-Dividend Date | Sept 29, 2022 |
| 1y Target Est | N/A |
- Business Wire
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash., May 26, 2022--Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association
- Motley Fool
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond
On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.
- Reuters
Japan's Takeda forecasts rebound despite full-year profit drop
Japan's Takeda Pharmaceutical Co said on Wednesday its 12-month operating profit slid 9.5%, although the country's largest drugmaker forecast a rebound for the current year. Chief Executive Christophe Weber said that core operating profit, which strips out impairments and other non-recurring items, would likely exceed 1 trillion yen this fiscal year, and the company's financials would become clearer now that its 2019 absorption of Shire Plc is complete. Takeda is domestically producing the COVID-19 vaccine, developed by Novavax Inc, which was approved by Japanese regulators last month.
